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ABSTRACT
B-cell chronic lymphocytic leukemia (CLL) is characterized by differential BCR 
signaling and autoimmune complications. Complement modulates B-cell function 
via C3d and CD21 cross-linked to the B-cell receptor (BCR). We hypothesized that 
CD21 contributes to BCR signaling and participates in the autoimmunity associated 
with CLL. We analyzed CD21 expression on 106 CLL patient samples and matched 
serum from 50 patients for the presence of soluble CD21 and autoantibodies to CR2, 
CR1, MCP and FH. CD21 expression on CLL B-cells was significantly lower than that 
expressed on B-cells from age-matched controls (P < 0.0001) and was inversely 
correlated with soluble CD21 (r2 = –0.41). We found no evidence of autoantibody to 
any complement regulator. Low CD21 expression correlated to prognostic subsets 
of CLL patients, i.e. cases with unmutated IGHV genes (P = 0.0006), high CD38 
(P = 0.02) and high ZAP70 expression (P = 0.0017). Low CD21 expression was 
inversely correlated to the levels of phosphotyrosine induced in CLL cells following 
BCR ligation with αIgM (r2=–0.21). Importantly, lower CD21 expression was also 
predictive for reduced overall survival (P = 0.005; HR = 2.7). In conclusion, we 
showed that reduced expression of CD21 on CLL B-cells appears functionally relevant 
and was associated with poor clinical outcomes.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is a clinically 
heterogeneous disease and characterized by the clonal 
expansion of functionally incompetent B-cells in the 
lymph node, bone marrow and blood. Previous studies 
have shown two types of CLL based on their IGHV 
mutation status and it is now thought that unmutated CLL 
is derived from unmutated mature CD5+ B-cells whereas 
mutated CLL is derived from a distinct, CD5+CD27+, 
post-germinal center B-cell subset [1–3]. CLL cells 
display an activated B1 and regulatory B-cell phenotype 
[4, 5]; they are considered antigen experienced, possibly 
following recognition of self-antigen, with a very 
restricted BCR repertoire [6, 7]. CLL is characterized 
by constitutive activation of BCR signaling pathways 
but with variable responsiveness to antigen ligation; 
associated with co-expression of CD38 via ZAP70 [8–10]. 
It is widely accepted that BCR signaling leads to survival 
signals and resistance against anergy [11, 12]. The recent 
finding that BTK inhibitors (acting downstream of the 
BCR) can kill CLL cells has highlighted the important role 
of the BCR in the pathogenesis of CLL [13–15]. For a 
significant minority of patients autoimmunity is a clinical 
problem due to auto-immune hemolytic anemia, immune 
thrombocytopenia purpura and low immunoglobulins 
[16, 17].
CD21 participates in the BCR co-receptor complex 
(CD21, CD19 and CD81). Co-ligation of CD21 and the 
BCR by C3dg-opsonised antigen can result in a thousand-
fold reduction of the B-cell activation threshold [18–20] 
and is sufficient to protect B-cells from FAS-mediated 
apoptosis [21]. Natural ligands of CD21 include the C3 
activation fragments iC3b, C3dg and C3d [22]. CD21 
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plays an important role in the selection for high-affinity 
B-cells as well as the development and maintenance of 
B-cell memory [22]. While the BCR co-receptor function 
of CD21 predominates, CD21 also mediates effects 
independent of the BCR including the induction of the 
transcription factor NF-κB, the production of interleukin-6 
(IL-6) and the internalization of antigen [23, 24].
C3d, a key ligand for CD21, is generated through 
activation of the complement system via the alternative, 
classical or lectin pathway. This involves generation of 
C3 convertases followed by rapid control by complement 
regulators, such as CD46, CD55 and CD35 [25, 26]. 
Thus, any alteration of complement activation can result 
in increased ligand availability for CD21 and/or other 
cell bound complement regulators, which may result in 
increased B-cell signaling. Recent studies have shown 
that Rituximab, used to treat CLL, partially kills through 
complement-mediated mechanisms and indeed some CLL 
patients have reduced serum complement levels causing 
Rituximab resistance [27, 28].
CLL is characterized by constitutive BCR 
activation and subsequent NF-κB signaling, albeit with 
variable responsiveness of the BCR to antigen ligation 
[29]. Given the role of CD21 and its complement ligands 
we wished to study their potential role with respect to 
BCR signaling, tyrosine phosphorylation, autoimmunity 
and clinical outcome in CLL. We found no evidence that 
autoantibodies to complement receptors and regulators 
caused lower expression of CD21 in CLL. Interestingly 
however, low CD21 expression was clearly linked with 
an increased CLL cell tyrosine phosphorylation potential 
after BCR crosslinking with sIg. Finally, lower CD21 
expression was significantly associated with other 
markers of poor prognosis and inferior clinical outcome 
in CLL.
RESULTS
We assessed the expression level of CD21 on 
CLL cells isolated from 106 patients and 20 age-
matched, healthy controls. The mean CD21 expression 
level on CLL cells was approximately 20% of that on 
normal B-cells which is comparable to previous reports 
[34–36] (Figure 1a). However, approximately 20% of 
CLL patients expressed CD21 levels within the normal 
range. In order to evaluate if C3d/immune complexes 
could dynamically affect CD21 expression levels on 
normal B-cells we exposed mouse B-cells to a C3d-Fc 
construct in the presence or absence of Fc blocking 
agents. Over a 72 h period both the Fc blocked and 
un-blocked cells demonstrated lower CD21 expression 
when exposed to C3d-Fc (Figure 1b), with the greatest 
effect noted with crosslinking of CD21 with Fc receptor. 
This data suggests that CD21 is down regulated in the 
presence of C3d and IgG and that crosslinking of Fc 
receptor to CD21 by autoantibody could result in a 
similar outcome.
Soluble CD21 levels in serum are inversely 
correlated with surface expression of the antigen 
on CLL B-cells
Matched serum was available for a subset of the CLL 
patients in this study (n = 50). We therefore investigated 
whether surface expression of CD21 was associated with 
soluble CD21 in the patients’ serum. There was a strong 
inverse correlation between surface CD21 expression 
and soluble CD21 in the serum (r2 = –0.41) suggesting 
that some patients may be more prone to CD21 shedding 
(Figure 1c). Soluble CD21 was significantly higher 
in patients with unmutated IGHV genes (P = 0.0014; 
Figure 1d) and there was a trend towards elevated soluble 
CD21 in patients with advanced Binet stage disease 
(P = 0.07; Figure 1e) and those with high ZAP70 expression 
(P = 0.08; Figure 1f).
No evidence of autoantibodies to complement 
regulators associated with CLL
Autoantibodies to CD21 or other surface regulators 
could explain the lower CD21 levels commonly found 
on CLL cells; autoimmune phenomena are a feature 
of some CLL patients [37]. We hypothesized that CLL 
patients might produce autoantibodies to complement 
regulators and modify the survival of CLL B-cells. 
Using established ELISA protocols, we analysed 50 
normal blood donor control (BDC) samples and 50 CLL 
samples for reactivity with recombinant proteins (CD21, 
CD35 and CD46) or factor H (FH) isolated from serum. 
Using this approach, low reactivity with all surface-
bound complement regulators with the exception of 
CD35 was noted (Figure 2b). Both patient and control 
groups generated a broad range of titers, likely indicating 
natural blood group alloantigen differences, which were 
not significantly different between CLL patient and 
normal serum samples. In all other cases transformation 
of background subtracted OD450 values to relative 
units (RU) using a positive control antibody as a 
standard curve [30] confirmed that no samples reached 
the nominal 100 RU cut-off for positivity used as a 
criterion in the FH autoantibody ELISA [30]. Neither 
did they exceed levels measured in the normal controls 
using a 0.975 fractile of the BDC group to determine 
autoantibody positivity as recommended by the 
International Federation of Clinical Chemistry for data 
with non-normal distribution. Furthermore, western blot 
analysis of the highest samples confirmed non-specific 
reactivity (data not shown). The presence of significant 
autoantibodies to CD21, CD35 or CD46 in these patients 
is therefore unlikely.
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Low CD21 expression level correlates with other 
prognostic indicators
We next established if CD21 expression correlated 
with stage of disease or the other prognostic markers 
including CD38, ZAP70 or unmutated IGHV. We found 
that low CD21 expression level significantly correlated 
with all markers of poor prognosis (Figure 3a–3d). The 
greatest statistical correlation is with unmutated IGHV and 
ZAP70, consistent with their previously described roles in 
BCR signaling.
Cells with low CD21 expression demonstrate 
greater p-tyrosine potential
CD38+ CLL cells have been shown to display an 
increased p-tyrosine (p-TYR) response following BCR 
crosslinking [9]. Thus, we examined if lower CD21 
expression levels also correlated with this phenomenon. 
Our analysis demonstrated that BCR crosslinking on CLL 
cells with lower CD21 expression yielded significantly 
greater p-TYR response than if the BCR was cross linked 
on CLL cells with normal levels of CD21 (Figure 4a, 4b).
Figure 1: CD21 expression on normal B-cells and CLL B-cells. A. CD21 expression was quantified on the surface of B-cells 
isolated from normal individuals or patients with CLL and stained for CD19, CD5 and CD21 using multi-colour flow cytometry. The 
MESF of CD21 expression on 5000 CD19+ cells are shown. B. CD21 expression measured on the surface of A20–2a3 cells after 72 hr 
incubation with (dashed grey line) or without mouse C3d-FC (solid grey histogram) or with FC block followed by mouse C3d-Fc (black 
line) or secondary antibody only (thin grey line). 5000 events were analysed, representative of 3 experiments. C. Categorical prognostic 
sub-groups of the CLL cohort were assessed for their expression of sCD21 using sandwich ELISA, D. CLL samples with unmutated IGHV 
genes, E. Binet stage B/C samples and F. ZAP70+ CLL all showed increased sCD21.
d)
e) f )
c)
a) b)
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Low CD21 expression on CLL B-cells identifies a 
subset of patients with shorter overall survival
Based on the data above it appeared that CD21 was 
a marker of progressive CLL. Analysis of survival was 
thus plotted using CD21 as a categorical marker using 
median expression to segregate the patients. Patients with 
≤ median levels of CD21 expression had a much poorer 
prognosis than those with > median CD21 expression 
(Figure 5). Only 30% of patients with low CD21 were 
alive at 20 years post diagnosis (median survival was 
14.7 years) compared to nearly 65% survival for patients 
with higher levels of CD21 (median survival > 25 years). 
These data indicate that low CD21 expression on CLL 
B-cells is another readily assessable marker of disease 
progression and prognosis.
DISCUSSION
Given the recent data outlining the importance of 
the BCR in the pathogenesis of CLL we wished to explore 
the potential role of the known BCR co-receptor CD21 
and its complement regulatory components. Consistent 
with earlier studies we found that CD21 expression 
was significantly lower in CLL cells which contradicts 
a smaller study showing no significant difference [38]. 
Figure 2: Autoantibody ELISA. Serum from 50 blood donor controls (BDC) and 50 CLL patients were analysed for autoantibodies 
to A. CD21 (SCR1–2), B. CD35, C. CD46 and D. Factor H by ELISA. In each case, mean of subtracted data for each individual was 
converted to relative units (RU) using a standard curve generated using a mAb (A, C) or known positive (B, D). Each individual serum 
sample was measured in triplicate and the mean RU value potted. Population mean is indicated by the solid line and the 97.5 fractile of the 
BDC illustrated by the dashed line.
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Furthermore, we found a strong inverse correlation 
between surface CD21 expression on the malignant B-cells 
and soluble CD21 found in the patients’ serum, similar to 
that noted in another recent study [39]. Of note, 10 patients 
analyzed herein had an 11q deletion and CLL B-cells 
expressing low levels of CD21. Therefore, reduced CD21 
expression on CLL, is likely a mixture of transcriptional 
modifications [34], deletion of 11q [40], and increased 
activity of matrix metalloproteases [41], known to occur 
in CLL [42] and other disease scenarios such as RA/SLE 
[43]. We can speculate that the increased soluble CD21 
and soluble CD23 seen in CLL is likely a consequence 
of a positive feedback mechanism where soluble CD21 
stimulates monocyte activation via CD23. This may result 
in increased MMP activity which, given the described role 
of soluble CD23, could cleave both CD21 and CD23 from 
CLL cells [44, 45]. DotScan technology has been used to 
establish differential arrays of CD markers associated with 
CLL progression [46], but these do not include CD21. Our 
study underlines that absolute cell surface expression level 
of signaling molecules as compared to their presence or 
absence on CLL may be of equal importance.
We clearly demonstrate that lower CD21 expression 
had a functional consequence, as it was associated 
with greater BCR signaling as evidenced by tyrosine 
phosphorylation. We clearly demonstrated an association 
between lower expression levels of CD21 on CLL cells and 
poorer clinical prognosis. Low CD21 expression and other 
markers of poor prognosis such as advanced Binet stage, 
CD38+, ZAP70+ and unmutated IGHV correlated with a 
worse clinical outcome. Thus, low CD21 expression on 
CLL cells represents an additional prognostic biomarker 
intimately involved in BCR signaling.
CD38+ CLL cells are reported to express higher 
levels of ZAP70 [47], a molecule known to enhance 
BCR signaling [8]. In light of our data, we might 
Figure 3: CD21 expression was significantly lower in high-risk prognostic sub-groups of CLL patients. Categorical 
prognostic sub-groups of the CLL cohort were assessed for their expression of CD21 using multicolor flow cytometry. A. Binet stage B/C 
samples B. CD38+ CLL cells C. ZAP70+ CLL cells and D. CLL samples with unmutated IGHV genes all showed significantly reduced 
CD21 expression.
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speculate that CD38, ZAP70 and CD21 are part of a 
common signalosome, which has arisen as part of disease 
progression. The strongest association noted in this study 
was between low CD21 expression and unmutated IGHV 
genes. This supports the hypothesis that the array of 
changes observed in CLL cells is linked to reactivity to 
self-antigen. It is also notable that the cellular features of 
CLL cells with mutated IGHV genes (largely unresponsive 
to anti-IgM) are similar to B-cells that have undergone 
receptor desensitization following chronic antigen 
stimulation [48].
Furthermore, there is now increasing interest in 
CD21lo (/negative) B-cells in association with autoimmune 
conditions [49, 50] and there may be common 
mechanism(s) driving the generation of these B-cells in 
both disease settings. CLL patients have an increased 
risk of the development of autoimmunity, including 
autoimmune hemolytic anemia, Evan’s syndrome, 
idiopathic thrombocytopenia purpura (ITP), Hashimoto’s 
thyroiditis, vasculitis and rheumatoid arthritis [37]. Could 
this be linked to the low CD21 expression? Certainly, 
CD21 expression level is directly linked to self-tolerance 
[51] and reduced expression levels have been suggested as 
a risk factor in developing autoimmunity [52]. Increased 
C3d production during inflammation may lead to reduced 
CD21 surface expression [53] and this is supported 
by our data with C3d-Fc and chronic CD21 signaling 
[54]. A further consideration was that autoantibodies to 
CD21, as seen in rheumatoid arthritis [55], could provide 
survival signals for autoreactive B-cells and potentiate 
disease. Our analysis herein establishes that no antibodies 
directed against CD21 or CD35, or key complement 
regulators exist that could mediate such survival signals. 
Furthermore, although our in vitro data indicates that 
CD21 levels can be markedly down-regulated on exposure 
to C3d-Fc immune-complexes, no overt signaling changes 
were noted. This suggests that this aspect may not be 
causal for the changes observed in CLL.
In conclusion, our data indicate that low CD21 
expression on CLL cells is intrinsically a marker of poor 
Figure 4: Analysis of the change in phosphotyrosine following B-cell receptor crosslinking with anti-IgM. CLL cells 
were left untreated or treated with anti-IgM for ten minutes. They were then fixed and stained with a PE conjugated anti-phosphotyrosine 
antibody (PY20) and fluorescence was measured by flow cytometry. A. CD21hi samples showed significantly less response to anti-IgM 
than CD21lo samples. B. PY20 MESF and CD21 MESF levels were plotted for each patient at baseline and the data illustrates basal 
phosphotyrosine does not correlate with CD21 expression. C. The change in phosphotyrosine was plotted against CD21 expression as 
continuous variables and linear regression analysis was performed. There was a negative correlation between the variables suggesting that 
high CD21 expression on CLL cells was associated with a blunted response to B-cell receptor crosslinking with anti-IgM.
a)
b) c)
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prognosis in the disease and support the growing evidence 
that BCR cell signaling pathways play a key role in 
modulating the clinical course of this disease. It remains 
unclear, whether altered CD21 expression contributes to 
malignancy or is a consequence of the disease. To date, 
investigations relating to the ability of CLL cells to signal 
have focused on ligation of the BCR using anti-IgM 
and IgD antibodies [9]. Although differential signaling 
between CLL cells and controls was observed, they did 
not relate to altered IgM, CD20 or CD79b expression 
levels. The present study identifies loss of CD21 as a 
potential factor in modulation of these signals and that 
further studies are required to delineate the integral roles 
of CD21, CD38, ZAP70 and IGHV mutation status in 
BCR signaling and how they may alter the responsiveness 
of CLL cells to small molecule inhibitors
MATERIALS AND METHODS
Patient recruitment
For ELISA analysis, serum was donated by 100 
normal healthy blood donors (blood donor controls, BDC; 
normally distributed, ranging from 17 to 72 years of age, 
median age 46, 54% female, 98% White-Caucasian) via 
the blood transfusion service (NHSBT, Newcastle upon 
Tyne). Peripheral blood was obtained from 106 serially 
collected CLL patients (see Table 1 for clinical profile) 
and 20 age-matched normal controls following informed, 
written consent in accordance with the Declaration of 
Helsinki and with local ethical committee approval 
(02/4806). Patient samples were collected based on a 
confirmed diagnosis of CLL.
Antibodies
Purified GB24 (mouse monoclonal raised 
against human MCP (CD46) kindly gifted by Prof 
John Atkinson/Dr Paula Bertram (School of Medicine, 
Washington University, St. Louis, MO, USA). Purified 
171 (BD Pharmingen, Oxford, UK) Knops Antigen, Kna 
(International blood group reference laboratories, NHS 
BTS, Bristol, UK). Goat anti-human IgG specific-HRPO 
and sheep anti-mouse IgG HRPO were obtained from 
Stratech Scientific (UK)
ELISA
Autoantibody ELISA
The autoantibody ELISAs were carried out as 
previously described [30, 31]. In brief, 96-well plates were 
coated with 2–5 μg/ml of recombinant (r)CD21 (scr1–2), 
rCD35, rCD46 or purified factor H in phosphate buffer 
saline (PBS) and incubated overnight at 4°C. A PBS only 
(no coat) plate was also included. Plates were blocked 
with PBS, 0.1% Tween 20 (PBST) and sera, diluted 1/50 
in PBST, was added in triplicate wells for 1 hour at room 
temperature. The plates were washed with PBST and 
bound antibody detected with goat anti-human IgG-HRPO 
(1/20,000). Tetramethylbenzidine (TMB; AbDserotec) was 
Figure 5: The prognostic impact of CD21 expression in CLL. A. The median expression of CD21 was determined and the 
cohort was categorized into CD21lo and CD21hi subsets. CLL patients with a CD21hi phenotype had a significantly inferior outcome when 
compared to CD21lo patients.
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used to develop the assay. The absorbance at 450nm was 
read (SpectraMax 190; MDS Analytical Technologies, 
Ltd., Coventry, UK). Readings from the PBS only plate 
were subtracted from the antigen plate data and means 
calculated for triplicates. Monoclonal antibodies (171 
and GB24 for CD21 and CD46, respectively) and known 
positive antisera (for CR1 and factor H, Knops antigen 
positive and ‘French’ positive, respectively [30, 31]) were 
included as positive controls. Pooled normal healthy donor 
serum and secondary antibody only (goat anti-mouse and 
goat anti-human IgG HRPO only) served as negative 
controls.
Detection of sCD21
All steps were carried out at room temperature 
for 1 hour unless stated. Nunc MaxisorbTM plates were 
coated with 10 μg/ml of monoclonal antibody 171 [32] 
in pH 9.6 carbonate buffer and incubated overnight. 
Plates were blocked with PBS/1% bovine serum albumin 
(BSA). Sera, diluted 1/50 in PBS/BSA, were added 
in triplicate. The plates were washed with PBS 0.01% 
Tween20 (4 times) and bound antibody detected with 
an affinity purified sheep anti-human CD21 (1/2000; 
AF4909, R&D systems, UK) diluted in PBS/BSA. After 
washing, bound antibody was detected using a donkey 
anti-goat-HRPO (1/5000; Stratech Scientific ltd, UK) 
antibody. Tetramethylbenzidine (TMB; AbDserotec) was 
used to develop the assay as above. Average of ‘no serum/
background’ wells was subtracted from all samples and the 
average of each triplicate for each sample is shown as an 
adjusted OD 450 value.
Flow cytometry
CD21, CD38 and ZAP-70 expression
Cell surface expression of CD21 and CD38 were 
examined by four-color flow cytometry. In brief, CLL cells 
were labeled with CD5-FITC, CD38-PE, CD21-PERCP/
cy5.5 and CD19-APC. CD21 expression was recorded for 
each sample as mean fluorescence intensity (MFI) values 
and subsequently converted to molecules of equivalent 
soluble fluorochrome (MESF) in order to standardize the 
data and control for day-to-day variation in the Accuri C6 
cytometer performance (Becton Dickinson). A calibration 
curve was constructed by monitoring a mixture of 
Table 1: Clinical characteristics of the CLL discovery cohort (n = 106)
Factor Subset Number
Median Age 66 years
Range 32 – 91 years
Median Follow-up 9.6 years
Required treatment Treated 45
Untreated 61
Binet stage A 68
B/C 38
CD38 expression <20% 59
≥20% 47
Genetics 11q- / 17p- 13
N / O 68
Not Determined 25
IGHV Status <98% 76
≥98% 28
Not Determined 2
ZAP-70 expression <20% 59
≥20% 47
11q- and 17p-: any FISH or karyotypic abnormality of 11q or 17p
N: No detectable cytogenetic aberration by fluorescence in situ hybridization (FISH)
O: Other cytogenetic abnormality (excluding 11q- or 17p-)
IGHV status: <98% sequence homology with the closest germline sequence (mutated); ≥98% sequence homology with the 
closest germline sequence (unmutated)
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fluorospheres (Dako) labeled with known amounts of 
fluorochrome. For categorical analysis, </≥ the median 
MESF value for CD21 was used to divide the cohort. 
The cut-off point used for CD38 positivity in the CLL 
population was ≥20%. Cytoplasmic ZAP70 expression 
was also determined by flow cytometry as described 
previously and the cut-off point for positivity was ≥20% 
[33]. The expression of CD21 on normal B-cells was 
determined by gating CD19+ B-cells.
Intracellular expression of tyrosine phosphorylated 
proteins
CLL lymphocytes were analyzed by three-
color immunofluorescent staining using CD5 and 
CD19 surface antigenic markers in conjunction with a 
PE-labeled phosphorylated-tyrosine antibody (PY20). 
Changes in phosphorylated tyrosine were monitored 
before and after BCR cross-linking. Briefly, BCR 
ligation was achieved by the addition of 20 μg/ml goat 
anti-IgM (Southern Biotechnology Associates) for 
15 mins at 37°C. Subsequently the cells were labeled 
with CD5-PE and CD19-APC and then fixed and 
permeabilized using a Fix and Perm kit according to the 
manufacturer’s instructions (Caltag). The cells were then 
labeled with a FITC-phosphorylated-tyrosine (PY20) 
antibody (Santa Cruz Biotech) and analyzed on an 
Accuri C6 flow cytometer. At least 10,000 events were 
acquired from each sample and the mean recorded. The 
MFI values for phosphorylated-tyrosine were converted 
to MESF values using fluorosphere-derived calibration 
curve as described above.
IGHV mutational analysis
Amplification and analysis of immunoglobulin 
(IGHV) gene mutation status was assessed using 
BIOMED II primers as described previously [32]. IGHV 
sequences were compared with the IGMT database 
(http://imgt.cines.fr) and samples with ≥98% homology to 
germline sequences were considered unmutated.
Statistical analysis
Statistical analysis was carried out using Prism 6.0 
(Graphpad) and SAS version 9.3 software (SAS Institute). 
Normal distribution of the ELISA data was established by 
skewness, kurtosis and the Shapiro-Wilks tests. Univariate 
comparisons were made using the Student’s t-test for 
paired and unpaired observations. The correlation between 
CD21 expression and the change in phosphotyrosine 
(MFI) was performed using least squares linear regression. 
All data was confirmed as Gaussian or a Gaussian 
approximation using the omnibus K2 test. Overall survival 
(OS) for categorical sub-groups was assessed with the log-
rank test and displayed as Kaplan-Meier curves.
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